Date: 2011-09-13
Type of information: Series D financing round
Company: AM-Pharma (The Netherlands)
Investors: Ysios Capital Partners (Spain) - Kurma Life Science Partners (France) - Abbott (USA) - Shire (UK) - BB Biotech Ventures (Switzerland) - Idinvest Partners (France) - Forbion Capital Partners (The Netherlands) - Inventages Venture Capital (UK-Switzerland-New Zealand-Bahamas)
Amount: €29.2 million
Funding type: series D financing round
Planned used: This fundraising will enable AM-Pharma to advance its human recombinant form of human alakaline phosphatase from preclinical stages through to the end of phase II as a treatment for acute kidney injury. AKI is a serious condition in which the kidney function is damaged by severe inflammation (sepsis), surgery or contrast fluids. This kidney damage may then lead to patients undergoing dialysis treatment for the rest of their lives. Currently there is no effective treatment for AKI and over 700.000 AKI patients die each year. The AKI market represents a USD 2 billion opportunity. AP, an enzyme playing a protective role in anti-inflammatory conditions, has shown great potency in two AKI clinical phase II studies as well as in one Ulcerative Colitis study with bovine-derived AP. The new human recombinant AP that AM-Pharma developed will be assessed for its safety and efficacy during clinical development.
Others: * On September 13, 2011, AM-Pharma, a biopharmaceutical company focused on the preclinical and clinical development of Alkaline Phosphatase (AP) for treatment of severe inflammatory diseases, has announced that it has raised €29.2 million in Series D financing. The series D round was led by Ysios Capital Partners, co-led by Kurma Life Science Partners and supported by a consortium including the venture arms of two global Healthcare companies, Abbott and Shire, the European venture funds, BB Biotech Ventures and Idinvest Partners as well as existing investors, Forbion Capital Partners and Inventages Venture Capital. Joël Jean-Mairet of Ysios, Remi Droller of Kurma Life Sciences Partners and Klaus Breiner of BB Biotech Ventures will join and further strengthen the existing Supervisory Board comprising of Ashok Dhanrajgir, Bart Bergstein, David Brister and Eric Claassen.
Therapeutic area: Inflammatory diseases
